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Objective: This study explored the relationship between the histologic subtype of
thymoma according to the new World Health Organization histologic classification
and the clinical findings, as well as the prognostic significance of the classification.
Methods: A total of 130 patients with thymoma, who underwent resection at the
National Cancer Center Hospital, Tokyo, from 1962 to 2000, were studied retro-
spectively. The histologic subtype of thymoma was determined according to the
new World Health Organization histologic classification. The stage was also deter-
mined according to a modified Masaoka’s classification as stage I, II, III, IVa, or
IVb. To determine the factors that may affect the prognosis of thymoma, a multi-
variate analysis with Cox’s proportional hazards regression model was performed.
Results: The distribution of histologic subtype was type A (n  18), type AB (n 
56), type B1 (n  15), type B2 (n  29), and type B3 (n  12). A close correlation
was seen between the histologic subtype and stage (P .000). The overall survivals
at 5 and 10 years were 92% and 91%, respectively. The 5- and 10-year survivals
according to stage were 100% and 100% (stage I, n  40; stage II, n  54), 81%
and 76% (stage III, n 25), and 47% and 47% (stage IV, n 11), respectively. The
difference in survival between stage III and stage IV was significant (P  .000).
Patients with type A or AB thymoma demonstrated a 100% survival at both 5 and
10 years. Recurrences were seen in 12 patients with complete resection. According
to a multivariate analysis, tumor size (P  .001), completeness of resection (P 
.002), histologic subtype (P .011), and stage (P .00) were significant prognostic
factors.
Conclusion: The World Health Organization histologic classification significantly
correlated with the clinical stage. Tumor size, completeness of resection, histologic
subtype, and stage predicted the prognosis of thymoma.
Thymomas are neoplasms that arise from epithelial cells of the thy-mus.1,2 Because of their low incidence, wide range of histologicappearance, and unique biologic behavior, they have been a sourceof controversy for many years. The histologic classification of thy-moma in particular is still a topic of dispute.3-6
Bernatz and colleagues7 classified thymoma into 4 histologic subtypes according
to the relative proportion of epithelial cells and lymphocytes: predominantly lym-
phocytic, mixed, epithelial, and spindle cell. In many studies, no significant corre-
lation was observed between this histologic subtype and clinical behavior, and
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probably the only important prognostic determinant was
invasion.8-11 In 1985, Marino and Mu¨ller-Hermelink12 de-
veloped a new histologic classification of thymic epithelial
neoplasm based on the morphologic and functional resem-
blance of neoplastic epithelial cells to normal thymic cor-
tical and medullary epithelial cells: medullary, mixed, pre-
dominantly cortical, and cortical. In addition, they proposed
well-differentiated thymic carcinoma as an organotypic
low-grade carcinoma of the thymus.13 Some studies showed
that this classification was useful for predicting clinical
behavior,14-17 whereas others disputed its clinical rele-
vance.10,18 On the other hand, Moran and Suster19 presented
3 categories of thymic epithelial tumor based simply on the
grade of histologic atypia: thymoma, atypical thymoma, and
thymic carcinoma. Thus, several histologic classifications
for thymoma have been published, but the prognostic sig-
nificance of such histologic classification is still controver-
sial. Recently, the World Health Organization (WHO) his-
tologic typing of tumors of the thymus was published.20
Only a few studies have been performed to evaluate the
clinical and prognostic relevance of this histologic classifi-
cation.21-23
In this study, we retrospectively reviewed surgically
resected thymomas on the basis of the WHO histologic
classification and evaluated the classification’s clinical and
prognostic usefulness. We also performed a multivariate
analysis to determine which factors independently predicted
the prognoses of patients with thymoma.
Materials and Methods
Patients
In the 38-year period from 1962 to 2000, there were 152 patients
with thymoma at the National Cancer Center Hospital, Tokyo.
Eight patients who were treated initially elsewhere and 14 patients
for whom an adequate tissue specimen was not available for
pathologic review were excluded from the present study. There-
fore, a total of 130 patients with thymoma were considered for
review. Their pathologic and clinical features were studied retro-
spectively. The medical records were extensively reviewed in
terms of clinicopathologic issues, including allied disease, type of
operation, perioperative therapy, mode of recurrence, and progno-
sis. Total thymectomy was defined as the resection of the entire
thymus and mediastinal fatty tissue between both phrenic nerves;
thymomectomy was defined as the resection of thymoma leaving
only residual thymic tissue behind; complete resection was defined
as no macroscopic or microscopic residual tumor; and incomplete
resection was defined as evident macroscopic or microscopic re-
sidual tumor. Recurrence was defined as any evidence of tumor,
such as regrowth of tumor in the mediastinum, pleural dissemina-
tion, or pulmonary metastasis, detected by imaging or pathologic
examination during follow-up.
Pathology
In each case, 2 investigators (K.N. and Y.M.) reviewed the hema-
toxylin-eosin–stained formalin-fixed paraffin sections of surgically
resected thymoma specimens in our pathology file. The histologic
subtype of thymoma was further determined according to the
WHO classification20 as follows. Type A: a tumor composed of a
population of spindle or oval neoplastic thymic epithelial cells
lacking nuclear atypia and accompanied by few or non-neoplastic
lymphocytes. Type AB: a tumor in which foci with the features of
type A thymoma are admixed with foci rich in lymphocytes. Type
B1: a tumor that resembles the normal functional thymus in that it
combines large expanses with an appearance practically indistin-
guishable from normal thymic cortex with areas resembling thy-
mic medulla. Type B2: a tumor in which the neoplastic epithelial
component appears as scattered plump cells with vesicular nuclei
and distinct nucleoli among a heavy population of lymphocytes,
perivascular spaces are common and sometimes very prominent,
and a perivascular arrangement of tumor cells resulting in a pali-
sading effect may be seen. Type B3: a type of thymoma predom-
inantly composed of round or polygonal epithelial cells exhibiting
no or mild atypia admixed with a minor component of lympho-
cytes, resulting in a sheet-like growth of the neoplastic epithelial
cells. We also performed a careful histologic assessment to deter-
mine whether the tumor invaded the capsule.
Clinical Stage
A modified Masaoka’s classification24,25 was used for the clinical
staging of patients with thymoma, in which thymic tumors that
infiltrate into but not through the capsule still belong to stage I.
This staging system was identical to the WHO staging guidelines20
and can be summarized as follows. Stage I: encapsulated, a thy-
moma completely surrounded by a fibrous capsule of varying
thickness that is not infiltrated by tumor growth (thymic tumors
that infiltrate into but not through the capsule still belong in this
category). Stage II: minimally invasive, a thymoma surrounded by
a capsule that is focally infiltrated by tumor growth or that invades
the mediastinal fat (the capsular invasion needs to be complete for
the tumor to be placed in this category). Stage III: widely invasive,
a thymoma spreading by direct extension into adjacent structures
such as pericardium, large vessels, or lung. Stage IVa: with
implants, a thymoma in which tumor nodules separate from the
main mass are found on the pericardial or pleural surface. Stage
IVb: with lymph node or distant metastases, a thymoma that
involves 1 or more lymph nodes anatomically separate from the
main mass or that was accompanied by embolic metastases to
distant site.
Statistical Analyses
To compare frequencies among different groups, a 2 test or
Tukey’s significant difference test was used. Survival was mea-
sured from the day of the operation until death or the last follow-up
visit. The Kaplan-Meier method was used to estimate time to death
from thymoma-related causes and a 95% confidence interval.
Death resulting from worsening of myasthenia gravis (MG) was
considered thymoma-related. All deaths that were not related to the
tumor (thymoma) were excluded from the calculation of survival
curves. Deaths resulting from other causes were considered as
censored. Differences in survival were tested by the log-rank test.
To identify the factors that may affect the prognosis, a multivariate
analysis using Cox’s proportional hazards regression model was
performed. The present multivariate analysis included 7 variables:
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gender, age, presence of MG, completeness of resection, tumor
size, tumor stage, and histologic subtype. These analyses were
performed with SPSS version 11.0 statistical software (SPSS, Inc,
Chicago, Ill).
Results
Clinical Findings
There were 54 men and 76 women (male to female ratio,
0.72) who ranged in age from 15 to 83 years (mean age,
54  13 years). Sixteen patients (12%) had MG, occurring
preoperatively and postoperatively in 8 patients each. None
of the patients had allied diseases other than MG. Forty
patients (31%) were in stage I, 54 patients (42%) were in
stage II, 25 patients (19%) were in stage III, 10 patients
(7%) were in stage IVa, and 1 patient (1%) was in stage
IVb. The clinical profiles of 130 patients are summarized in
Table 1. A total of 124 patients (95%) underwent complete
resection. In contrast, complete resection was impossible for
6 patients (5%) because of extensive invasion to the neigh-
boring organs in 2 patients and multiple implants in the
thorax in 4 patients. Ten patients (8%) received periopera-
tive therapy: preoperatively in 3 patients, postoperatively in
6 patients, and both preoperatively and postoperatively in 1
patient. Four patients were treated with preoperative che-
motherapy. The preoperative chemotherapeutic regimens
were as follows: cisplatin 25 mg/m2, vincristine 1 mg/m2,
doxorubicin 40 mg/m2, and etoposide 80 mg/m2 for 2 cycles
(2 patients); cisplatin 60 mg/m2, cyclophosphamide 800
mg/m2, doxorubicin 45 mg/m2, and etoposide 80 mg/m2 for
2 cycles (1 patient); and cisplatin 80 mg/m2 and etoposide
60 mg/m2 for 2 cycles (1 patient). For postoperative ther-
apy, 6 patients received radiotherapy at 40 to 50 Gy (1
patient in stage II, 4 patients in stage III, and 1 patient in
stage IVa), and 1 patient received chemotherapy. The per-
centage of patients who received postoperative radiotherapy
was 1.8% (1/54) in stage II, 16% (4/25) in stage III, and
10% (1/10) in stage IVa.
Histologic Findings
With regard to histologic subtype, type A was found in 18
patients (14%), type AB in 56 (43%), type B1 in 15 (12%),
type B2 in 29 (22%), and type B3 in 12 (9%). The relation-
ship between tumor stage and histologic subtype is summa-
rized in Table 2. The proportion of tumors in an advanced
stage gradually increased from type A to type B3. There was
a striking correlation between stage and histologic subtype
(2 test, P  .000). One patient with type A thymoma had
pulmonary metastases before the operation. The clinical
features of each histologic subtype are presented in Table 3.
The frequency of association with MG tended to be higher
in patients with type B2 or B3 tumor than in those with
other histologic subtypes, although this difference was not
statistically significant. Despite the subtype as type A, 1
patient had MG. Patients with type B3 thymoma had sig-
nificantly larger tumors than those with other histologic
subtypes (Tukey’s significant difference test, P  .05).
Prognosis
The overall survivals at 5 and 10 years were 92% and 91%,
respectively. Survival according to the completeness of
resection is shown in Figure 1. Patients who underwent
complete resection (n  124) had significantly better sur-
vival than those with incomplete resection (n  6, log-rank
test, P  .000). However, there was no difference in sur-
vival between patients undergoing total thymectomy and
TABLE 1. The clinical profiles of treatment
Profiles No of patients (%)
Type of operation (Total No.  130)
Total thymectomy 71 (55)
Thymomectomy 55 (42)
Exploratory thoracotomy 4 (3)
Completeness of resection (Total No.  130)
Complete 124 (95)
Incomplete 6 (5)
Perioperative therapy 11 (8)*
Preoperative 4 (3)
Radiation therapy 0
Chemotherapy 4
Postoperative 7 (5)
Radiation therapy 6
Chemotherapy 1
*One patient had both preoperative and postoperative therapies.
TABLE 2. The relation between histologic subtype and
stage
Histologic
subtype
No of
patients
Stage
I II III IVa IVb
A 18 8 7 2 1
AB 56 28 22 6
B1 15 2 9 4
B2 29 2 14 6 7
B3 12 2 7 3
Total 130 40 54 25 10 1
TABLE 3. The clinical features of each histologic subtype
Histologic
subtype
Sex
(M/F)
Age (y) MG
(%)
Size (cm)
Mean  SD Range Mean  SD Range
A 8/10 60 16 23-83 1 (5) 7.9 3.7 2.0-12.5
AB 21/35 55 11 33-83 4 (6) 6.9 2.7 1.2-17
B1 4/11 56 13 35-72 1 (7) 6.9 2.8 3.5-15
B2 14/15 49 12 26-66 7 (24) 6.6 2.5 1.5-11
B3 7/5 49 17 15-79 3 (25) 11.5 7.3* 4.0-28
Total 54/76 54 13 15-83 16 (12) 7.4 3.7 1.2-28
MG, Myasthenia gravis.
*P  .05.
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those undergoing thymomectomy. Survival according to
tumor size is shown in Figure 2. Patients with a tumor less
than 10 cm in diameter (n  108) had significantly better
survival than those with a tumor 10 cm or larger (n  22,
log-rank test, P  .000). The survival curves according to
histologic subtype are shown in Figure 3. The 5- and 10-
year survivals according to the histologic subtype were
100% and 100% (type A and AB), 100% and 86% (type
B1), 85% and 85% (type B2), and 51% and 38% (type B3),
respectively. Because there were no thymoma-related
deaths among patients with type A and AB thymomas, the
difference in survival between type A and other histologic
subtypes, as well as between type AB and other histologic
subtypes, could not be tested. The differences in survival
between type B1 and B3 as well as between B2 and B3 were
significant (log-rank test, P  .000). The survival curves
according to the clinical stage are shown in Figure 4. The 5-
and 10-year survivals according to stage were 100% and
100% (stage I and II), 81% and 76% (stage III), and 47%
and 47% (stage IV), respectively. Because there were no
thymoma-related deaths among patients with stage I or
stage II thymoma, the difference in survival between stage
I and other stages, as well as between stage II and other
stages, could not be tested. The difference in survival be-
tween stage III and stage IV was significant (log-rank test,
P  .000). The presence of MG marginally affected the
survival. The 5-year survivals for patients with MG and
those without MG were 94% and 80%, respectively. The
difference was marginally significant (P  .0074).
Of 124 patients with complete resection, 12 (9.6%) ex-
perienced a recurrence. The details of patients with recur-
rence are shown in Table 4. There were 2 local recurrences,
3 distant metastases, 6 pleural disseminations, and 1 recur-
rence at an unknown site. Three of 18 patients (17%) with
type A thymoma had a recurrence. Two patients had pul-
monary metastasis, and 1 patient had local recurrence. One
of 56 patients (1.8%) with type AB thymoma had a pulmo-
nary metastasis. One of 15 patients (6.6%) with type B1
thymomas had pleural dissemination. Two of 29 patients
(7%) with type B2 thymoma had recurrence (1 local recur-
Figure 1. Survival according to the completeness of resection.
The 5- and 10-year survivals were 96% and 94% in patients with
complete resection and 33% and 33% in patients with incomplete
resection, respectively. The difference in survival between the 2
groups is significant (P  .000).
Figure 2. Survival according to tumor size. The 5- and 10-year
survivals were 97% and 95% in patients with a tumor less than 10
cm in diameter and 72% and 72% in patients with a tumor 10 cm
or larger, respectively. The difference in survival between the 2
groups is significant (P  .000).
Figure 3. Survival according to the histologic subtype. The 5- and
10-year survivals according to the histologic subtype were 100%
and 100% (type A and AB), 100% and 86% (type B1), 85% and 85%
(type B2), and 51% and 38% (type B3), respectively. The difference
in survival between type B2 and type B3 is significant (P  .000).
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rence and 1 pleural dissemination). Five of 12 patients
(42%) with type B3 thymoma had recurrence (4 pleural
dissemination and 1 at an unknown site). According to
tumor stage, 1 of 40 patients (2.5%) with stage I thymoma
and 1 of 54 patients (1.8%) with stage II thymoma had local
recurrence. The former patient had a cervical tumor, which
was initially believed to be a thyroid tumor, so he only
underwent tumor resection. However, the pathologic diag-
nosis of the resected specimen was thymoma. Although
there was no macroscopic or microscopic residual tumor,
the resection in this case may have been incomplete. Seven
of 25 patients (28%) with stage III thymoma had recurrence
(6 pleural dissemination and 1 at an unknown site).
During the follow-up period, 33 deaths occurred. Eleven
patients (33%) died of thymoma-related causes. The re-
maining 22 patients died of other causes (7 of other malig-
nancies, 5 of pneumonia, 4 of heart diseases, 2 of brain
diseases, 1 of renal failure, 1 of sepsis, and 2 of unknown
causes). None of the patients with stage I or II thymomas or
with type A or AB thymoma died of thymoma-related
causes.
Multivariate Analyses
Because of the striking correlation between stage and his-
tologic subtype, these 2 variables were each entered into
multivariate analyses together with 5 other variables (gen-
der, age, presence of MG, completeness of resection, and
tumor size). Therefore, 2 separate multivariate analyses
were performed with different combinations of 6 variables.
The results of each analysis are shown in Tables 5 and 6.
Tumor size (P  .001), completeness of resection (P 
.002), histologic subtype (P  .011), and stage (P  .00)
were noted as significant prognostic factors.
Discussion
The WHO histologic typing of tumors of the thymus was
first published in 1999.20 A few clinicopathologic studies
have examined the usefulness of this classification.21-23
Among these reports, only one, by Okumura and col-
leagues,23 evaluated the clinical and prognostic significance
of this classification, and they concluded that the histologic
subtype based on the WHO classification reflected the on-
cologic behavior of thymoma.
In this study, the histologic subtype based on the WHO
histologic classification could be determined in all 130
thymomas. Twelve of these were considered type B3 thy-
moma. Type B3 thymoma is defined as a thymoma predom-
inantly composed of epithelial cells with no or mild atypia.
In our series, several thymomas were actually composed of
more than 1 histologic subtype including B3. The WHO
classification does not clearly define how to deal with cases
involving type B3 thymomas. Kirchner and colleagues26
reported that a diagnosis of well-differentiated thymic car-
cinoma can be made only in cases in which more than 50%
of the tumor shows this typical morphology. On the other
hand, Quintanilla-Martinez and coworkers15,16 suggested
that tumors with any area in which this diagnostic histology
could be recognized should be classified as well-differenti-
ated thymic carcinoma. In the present study, we adopted the
latter criteria and included 3 such cases in type B3. These 3
cases followed aggressive clinical courses; therefore, the
diagnostic criteria described by Quintanilla-Martinez and
coworkers seem appropriate. The diagnostic criteria for type
B3 should be further refined and standardized.
Regarding the correlation between histologic subtype
and clinical findings of thymoma, the frequency of associ-
ation with MG tended to be higher in patients with type B2
or B3 tumor than in those with other histologic subtypes,
although this difference was not significant. We also found
that the histologic subtype based on the WHO classification
was closely related to the tumor stage. The proportion of
tumors in an advanced stage gradually increased from type
A to type B3. In regard to the prognosis of each histologic
subtype, patients with type A and AB thymoma had good
prognoses, with no thymoma-related deaths. In contrast, the
prognoses of patients with type B thymoma tended to grad-
ually worsen from B1 to B3. From a clinicopathologic
viewpoint, the WHO histologic classification seems to have
clinical and prognostic value. The relationship between
histologic subtype and sensitivity to chemotherapy and ra-
diotherapy could not be clearly determined in this study.
Further investigation is necessary.
Figure 4. Survival according to the tumor stage. The 5- and
10-year survivals according to stage were 100% and 100% (stages
I and II), 81% and 76% (stage III), and 47% and 47% (stage IV),
respectively. The difference in survival between stage III and
stage IV is significant (P  .000).
General Thoracic Surgery Nakagawa et al
1138 The Journal of Thoracic and Cardiovascular Surgery ● October 2003
G
TS
Several studies have shown that medullary and mixed
thymomas according to the Mu¨ller-Hermelink classifica-
tion, which are probably included in the type A and AB
histologic subtypes in the WHO classification, have a good
prognosis,12,17,18 and 1 author concluded that these kinds of
thymoma were benign tumors.16 On the other hand, Shimo-
sato and Mukai2 and Pan and colleagues21 indicated that it
was dangerous to consider these tumors as benign. In fact,
in our series, 2 type A thymomas and 1 type AB thymoma
had pulmonary metastases. Although most type A and AB
thymomas follow a benign clinical course, they are not
absolutely benign tumors.
Although factors such as completeness of resection, tu-
mor size, stage, and histology have been mentioned as
prognostic factors in thymoma,8, 9,16-18,27-30 the presence or
absence of tumor invasion has been uniformly recognized as
a prognostic factor.3,19 According to the present multivari-
ate analyses, the histologic subtype by the WHO classifica-
tion and tumor size should be recognized as factors that may
strongly affect the prognosis. Indeed, although staging ac-
cording to Masaoka’s classification24 reflected the progno-
sis, several important revisions of this staging system have
been strongly recommended.3,10,19 The definitions of stages
I and II, in which stage I is defined as a thymoma without
capsular invasion and stage II is defined as a thymoma with
capsular invasion, especially need to be revised. Our present
study demonstrated that there was no significant difference
in survival between stages I and II, with 5-year and 10-year
survival of 100%, respectively. Similar results have been
observed in several other studies.14,17,23,29 These results
clearly show that capsular invasion in thymoma has no
prognostic significance, and therefore capsular invasion in
thymoma should not be used in the staging system for
thymoma. The present stage I and stage II should be merged
and reclassified as stage I. Subsequently, the heterogeneous
stage III should be further divided into stage II and stage III.
This retrospective study clearly demonstrated that the
prognoses of patients were also affected by the histologic
TABLE 4. Clinicopathologic features of patients who had tumor recurrence after complete resection
Patient No.
(sex, age)
Histologic
subtype Stage Recurrence
Interval to recurrence
from operation
Treatment for
recurrent tumors Outcome
1
(F, 36) A I Local 16 y 8 mo Resection Alive at 15 y
2
(M, 59) A I PM 3 y Resection and CT Alive at 6 y
3
(F, 58) AB II PM 3 y Resection Alive at 15 y
4
(F, 28) B2 II Local 6 y Resection and RT Alive at 5 y
5
(F, 55) B1 III PD 6 y Resection DOT at 4 y
6
(M, 64) B2 III PD 6 y Resection Alive at 5 y
7
(F, 43) B3 III PD 18 y Resection Alive at 12 y
8
(F, 65) B3 III PD 1 y 5 mo CT DOT at 5 mo
9
(F, 42) B3 III PD 6 mo CT DOT at 11 mo
10
(F, 60) B3 III PD 4 mo CT DOT AT 2 y
11
(M, 15) B3 III Unknown Unknown Unknown DOT at 11 y
12
(M, 65) A IVb PM 2 y CT Alive at 6 y
PM, Pulmonary metastasis; PD, pleural dissemination; CT, chemotherapy; RT, radiation therapy; DOT, died of thymoma-related causes.
TABLE 5. Multivariate analysis (stage excluded)
Variables Risk ratio P value
Histologic subtype 2.89 .011
Complete resection 9.5 .002
Tumor size 1.26 .001
TABLE 6. Multivariate analysis (histologic subtype ex-
cluded)
Variables Risk ratio P value
Stage 5.08 .00
Tumor size 1.252 .01
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subtype of thymoma, and it was not the simple matter of
tumor progression according to stage. Therefore, in deter-
mining the therapeutic strategy of patients with thymoma,
the histologic subtype along with stage should be always
considered, although the uniform staging system should be
applied in any type of thymic epithelial tumors. The staging
system also should be further refined according to these
findings.
We are grateful to Dr Yukio Simosato, Visiting Professor,
Department of Pathology, Keio University School of Medicine, for
his advice on histologic interpretation of cases.
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